---
title: "Curis doses first five patients in TakeAim CLL combo trial of emavusertib, zanubrutinib"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294362171.md"
description: "Curis has dosed the first five patients in its TakeAim CLL Phase 2 study, evaluating the combination of emavusertib and zanubrutinib for chronic lymphocytic leukemia. The trial targets patients with residual disease despite long-term zanubrutinib therapy to deepen responses and support fixed-duration treatment. Management reported early signs of tolerability and improved responses. Initial results are expected in December 2026."
datetime: "2026-07-30T12:07:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294362171.md)
  - [en](https://longbridge.com/en/news/294362171.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294362171.md)
generator: "portal-rs"
---

# Curis doses first five patients in TakeAim CLL combo trial of emavusertib, zanubrutinib

-   Curis dosed the first five patients in its TakeAim CLL Phase 2 study testing emavusertib with zanubrutinib in chronic lymphocytic leukemia. \* Initial results have not been presented; early CLL data in 5–10 patients is expected in December 2026. \* The study targets patients with residual disease despite long-term zanubrutinib, aiming to deepen responses and support a fixed-duration treatment approach. \* Management flagged early signs that the emavusertib-zanubrutinib combination is tolerable, with early indications of improved responses in a small group. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE15746) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md)

## Related News & Research

- [CRIS: Emavusertib shows strong response rates in PCNSL and advances in CLL, pending further funding](https://longbridge.com/en/news/293464781.md)
- [CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials](https://longbridge.com/en/news/293485845.md)
- [Oryzon Genomics wins US notice of allowance for iadademstat-gilteritinib AML patent application](https://longbridge.com/en/news/297475261.md)
- [Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation](https://longbridge.com/en/news/297813603.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**